Abcam RabMAb recombinant rabbit monoclonal antibodies

Abcam has combined the advantages of its RabMAb rabbit monoclonals with recombinant technology to deliver high-performance antibodies. In order to provide users with antibodies that have good sensitivity and a high degree of consistency, the company has engineered recombinant versions of its RabMAb rabbit monoclonal antibodies, delivering a number of advantages.

Abcam currently offers over 10,000 recombinant RabMAb antibodies that provide low-background, high-specificity, high-affinity (10^-12 kD possible) and diverse epitope recognition, with recombinant technology adding high consistency and reproducibility, improved specificity and animal-free production.

In addition to the benefits of recombinant RabMAb antibodies, Abcam validates each one in key applications (WB, IHC, ICC/IF, IP and flow cytometry) and species (human, mouse and rat). They are affinity purified to remove any impurities that could otherwise lead to non-specific signal.

Abcam provides over 3000 directly conjugated recombinant RabMAb antibodies, including popular dyes and enzymes. The company further includes knockout validation via CRISPR technology for a growing number of antibodies.